These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 23602600)

  • 1. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
    Chen KL; Lin CC; Cho YT; Yang CW; Sheen YS; Tsai HE; Chu CY
    JAMA Dermatol; 2016 Mar; 152(3):340-2. PubMed ID: 26649681
    [No Abstract]   [Full Text] [Related]  

  • 3. Erlotinib-induced pustular eruption.
    Cusano F; Ferrara G; Barletta E; Ingordo V
    G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
    Takashima N; Kimura T; Watanabe N; Umemura T; Katsuno S; Arakawa K; Fukatsu M; Nakamura N; Nishiyama O; Kataoka K; Kondoh Y; Taniguchi H
    Onkologie; 2012; 35(12):747-52. PubMed ID: 23207620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
    Giuliani J; Marzola M
    Cutan Ocul Toxicol; 2013 Sep; 32(3):248-51. PubMed ID: 23368942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
    Giuliani J; Marzola M
    Arch Dermatol Res; 2013 Sep; 305(7):653-8. PubMed ID: 23536039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of targeted therapy in non-small-cell lung cancer management.
    Ricciardi S; Tomao S; de Marinis F
    Clin Lung Cancer; 2009 Jan; 10(1):28-35. PubMed ID: 19289369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reviewing the safety of erlotinib in non-small cell lung cancer.
    Reck M; Mok T; Wolf J; Heigener D; Wu YL
    Expert Opin Drug Saf; 2011 Jan; 10(1):147-57. PubMed ID: 21138395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
    Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular rash during therapy with erlotinib (Tarceva).
    Gerdes S; Mrowietz U
    J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
    Seiverling EV; Fernanadez EM; Adams D
    J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
    J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.